このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Coloplast マネジメント

マネジメント基準チェック /44

Coloplast'sの CEO はKristian Villumsenで、 Dec2018年に任命され、の在任期間は 5.67年です。の年間総報酬はDKK 23.30Mで、 51.5%給与と48.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.045%を直接所有しており、その価値は€ 12.22M 。経営陣と取締役会の平均在任期間はそれぞれ6.3年と6.6年です。

主要情報

Kristian Villumsen

最高経営責任者

DKK 23.3m

報酬総額

CEO給与比率	51.5%
CEO在任期間	5.8yrs
CEOの所有権	0.05%
経営陣の平均在職期間	6.4yrs
取締役会の平均在任期間	6.7yrs

経営陣の近況

Recent updates

CEO報酬分析

Coloplast の収益と比較して、Kristian Villumsen の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	DKK 5b
Mar 31 2024	n/a	n/a	DKK 5b
Dec 31 2023	n/a	n/a	DKK 5b
Sep 30 2023	DKK 23m	DKK 12m	DKK 5b
Jun 30 2023	n/a	n/a	DKK 5b
Mar 31 2023	n/a	n/a	DKK 5b
Dec 31 2022	n/a	n/a	DKK 5b
Sep 30 2022	DKK 21m	DKK 12m	DKK 5b
Jun 30 2022	n/a	n/a	DKK 5b
Mar 31 2022	n/a	n/a	DKK 5b
Dec 31 2021	n/a	n/a	DKK 5b
Sep 30 2021	DKK 22m	DKK 11m	DKK 5b
Jun 30 2021	n/a	n/a	DKK 5b
Mar 31 2021	n/a	n/a	DKK 4b
Dec 31 2020	n/a	n/a	DKK 4b
Sep 30 2020	DKK 20m	DKK 11m	DKK 4b
Jun 30 2020	n/a	n/a	DKK 4b
Mar 31 2020	n/a	n/a	DKK 4b
Dec 31 2019	n/a	n/a	DKK 4b
Sep 30 2019	DKK 17m	DKK 10m	DKK 4b
Jun 30 2019	n/a	n/a	DKK 4b
Mar 31 2019	n/a	n/a	DKK 4b
Dec 31 2018	n/a	n/a	DKK 4b
Sep 30 2018	DKK 11m	DKK 6m	DKK 4b
Jun 30 2018	n/a	n/a	DKK 4b
Mar 31 2018	n/a	n/a	DKK 4b
Dec 31 2017	n/a	n/a	DKK 4b
Sep 30 2017	DKK 10m	DKK 6m	DKK 4b

報酬と市場: Kristianの総報酬 ($USD 3.48M ) は、 German市場 ($USD 5.49M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Kristianの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Kristian Villumsen (54 yo)

5.8yrs

在職期間

DKK 23,300,000

報酬

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Kristian Villumsen	President & CEO	5.8yrs	DKK 23.30m	0.045% DKK 11.8m
Anders Lonning-Skovgaard	Executive VP & CFO	10.2yrs	DKK 11.90m	0.0012% DKK 308.2k
Allan Rasmussen	Executive Vice President of Global Operations	10.2yrs	DKK 10.50m	0.011% DKK 3.0m
Nicolai Andersen	Executive Vice President of Innovation	no data	DKK 10.00m	データなし
Paul Marcun	Executive Vice President of Growth	5.7yrs	DKK 12.00m	0.014% DKK 3.5m
Thomas Barfod	Senior Controller & Employees Representative Director	no data	DKK 450.00k	0.000020% DKK 5.2k
Ellen Bjurgert	Vice President of Investor Relations	7.9yrs	データなし	データなし
Dennis Kaysen	Director of Corporate Communications	no data	データなし	データなし
Dorthe Ronnau	Senior Vice President of People & Culture	2.7yrs	データなし	データなし
Alain Morvan	Senior Vice President of Sales Europe	12.4yrs	データなし	データなし
Rasmus Møller	Senior Vice President of Wound & Skin Care	4yrs	データなし	データなし
Manu Varma	Senior Vice President of Chronic Care - North America	6.4yrs	データなし	データなし

6.4yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: CBHDの経営陣は経験豊富で経験豊富です（平均在職期間は6.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Thomas Barfod	Senior Controller & Employees Representative Director	18.7yrs	DKK 450.00k	0.000020% DKK 5.2k
Carsten Hellmann	Independent Director	6.8yrs	DKK 690.00k	0.0027% DKK 697.5k
Lars Rasmussen	Chairman of the Board	5.8yrs	DKK 1.84m	0.0054% DKK 1.4m
Niels Louis-Hansen	Deputy Chairman	56.7yrs	DKK 938.00k	1.93% DKK 503.6m
Marianne Wiinholt	Independent Director	3.8yrs	DKK 880.00k	0.00022% DKK 57.5k
Jette Nygaard-Andersen	Independent Director	8.8yrs	DKK 600.00k	データなし
Nikolaj Gundersen	Employees Representative Director	6.7yrs	DKK 450.00k	データなし
Roland Pedersen	Employees Representative Director	6.7yrs	DKK 450.00k	0.00072% DKK 188.1k
Annette Bruls	Independent Director	2.8yrs	DKK 600.00k	データなし

6.7yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: CBHDの取締役会は経験豊富であると考えられます ( 6.6年の平均在任期間)。

Coloplast マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Deputy Chairman recently bought €5.4m worth of stock

Less than half of directors are independent

Coloplast Announces Executive Changes

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Recent updates

Third quarter 2024 earnings released: EPS: kr.5.67 (vs kr.5.99 in 3Q 2023)

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

First half dividend of kr.5.00 announced

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

New major risk - Financial position

Second quarter 2024 earnings released: EPS: kr.5.57 (vs kr.5.44 in 2Q 2023)

First quarter 2024 earnings released

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Now 21% undervalued after recent price drop

Full year 2023 earnings released

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Deputy Chairman recently bought €5.4m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

New minor risk - Shareholder dilution

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings released: EPS: kr.5.99 (vs kr.6.07 in 3Q 2022)

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Upcoming dividend of kr.15.00 per share

Less than half of directors are independent

Coloplast Announces Executive Changes

Full year 2022 earnings released: EPS: kr.22.17 (vs kr.22.67 in FY 2021)

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Third quarter 2022 earnings released

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings released

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Independent Director Birgitte Nielsen has left the company

Upcoming dividend of kr.14.00 per share

Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020)

Third quarter 2021 earnings released: EPS kr.5.89 (vs kr.4.69 in 3Q 2020)

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Second quarter 2021 earnings released

New 90-day low: €117

First quarter 2021 earnings released

Revenue beats expectations

New 90-day high: €136

New 90-day low: €119

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

New 90-day low: €122

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Revenue misses expectations

New 90-day low: €128

New 90-day low: €130

New 90-day low - €132

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Earnings released

New 90-day low - €137

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

マネジメント基準チェック /44